ZURA Stock Summary and Trading Ideas (Zura Bio Limited - Class A | NASDAQ:ZURA)

Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.

Zura Bio Limited - Class A trades on the NASDAQ stock market under the symbol ZURA.

As of January 14, 2026, ZURA stock price climbed to $5.37 with 233,377 million shares trading.

ZURA has a beta of 1.38, meaning it tends to be more sensitive to market movements. ZURA has a correlation of 0.05 to the broad based SPY ETF.

ZURA has a market cap of $349.15 million. This is considered a Small Cap stock.

The top ETF exchange traded funds that ZURA belongs to (by Net Assets): VXF, IWC, SBIO, AVSC, MSSM.

ZURA has outperformed the market in the last year with a price return of +169.8% while the SPY ETF gained +20.0%. ZURA has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +39.1% and +0.9%, respectively, while the SPY returned +4.4% and +0.5%, respectively.

ZURA support price is $4.83 and resistance is $5.49 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ZURA shares will trade within this expected range on the day.